European Society for Paediatric Nephrology (ESPN) 2025
October 15-18, 2025 | Athens, Greece
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Long-Term Efficacy, Safety, and Growth Outcomes in the Phase 3 ILLUMINATE-B Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Descriptive Analysis of Real-World Enrollment Data of Pediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE)
Kidney Function, Isolated Kidney Transplant, and Health-Related Quality-of-Life Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-Term Lumasiran
